The efficacy and safety of statin in combination with ezetimibe compared with double-dose statin in patients with high cardiovascular risk: A meta-analysis
| Autor: | Jun Yang, Yunyun Zhu, Shaoyi Lin, Qi Yao, Haochang Hu, Yushan Yu, Ting Liu, Hongyu Xu |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
safety
medicine.medical_specialty Statin Combination therapy Efficacy medicine.drug_class Atorvastatin Review Article 030204 cardiovascular system & hematology Gastroenterology combination therapy 03 medical and health sciences 0302 clinical medicine Pharmacotherapy Ezetimibe Internal medicine medicine Humans high cardiovascular risk 030212 general & internal medicine Adverse effect lcsh:R5-920 business.industry Therapeutic effect statin nutritional and metabolic diseases General Medicine medicine.disease Cardiovascular Diseases lipids (amino acids peptides and proteins) Drug Therapy Combination Hydroxymethylglutaryl-CoA Reductase Inhibitors business lcsh:Medicine (General) Dyslipidemia medicine.drug |
| Zdroj: | Bosnian Journal of Basic Medical Sciences Bosnian Journal of Basic Medical Sciences (2019) |
| ISSN: | 1840-4812 1512-8601 |
| Popis: | Currently, statins are the first-line therapies for dyslipidemia and atherosclerotic cardiovascular disease, however, their hypolipidemic effects have not been satisfactory. We performed a meta-analysis to compare lipid-lowering efficacy and safety of ezetimibe and statin combination therapy with double-dose statin monotherapy in patients with high cardiovascular risk. Fourteen studies involving 3,105 participants were included in the final analysis; 1,558 (50.18%) participants received ezetimibe and statin combination therapy and 1,547 (49.82%) received double-dose statin monotherapy. Eight studies reported the percentages of changes in several lipid parameters from baseline to endpoint in both groups. Lipid parameters changed more significantly in patients co-administered with ezetimibe and statin (low-density lipoprotein cholesterol [LDL-C]: MD = -9.39, 95% CI -13.36 to -5.42; non-high-density lipoprotein cholesterol [non-HDL-C]: MD = -10.36, 95% CI -14.23 to -6.50; total cholesterol [TC]: MD = -8.11, 95% CI -10.95 to -5.26; and triglyceride [TG]: MD = -5.96, 95% CI -9.12 to -2.80), with moderate to high heterogeneity among the studies. Two out of fourteen studies investigated several different statins. Our subgroup analysis showed that, compared with double-dose atorvastatin monotherapy, ezetimibe and atorvastatin combination therapy significantly decreased LDL-C, non-HDL-C, TC, and TG levels by 14.16%, 14.01%, 11.06%, and 5.96%, respectively (p < 0.001). No significant difference was found in the incidence of laboratory-related adverse events (AEs) between statin combination therapy and monotherapy. Overall, ezetimibe and statin combination therapy significantly decreased LDL-C, non-HDL-C, and TC levels in patients with high cardiovascular risk, among which ezetimibe combined with atorvastatin had the best therapeutic effect. Compared with ezetimibe and statin combination therapy, double-dose statin monotherapy did not increase the risk of AEs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|